Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C37H40FN7O3S |
| Molecular Weight | 681.822 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1CN(CC2=CC=C(C=C2)C3=CC=CC(=C3)N4C(=O)N([C@@H]5CC[C@@H](CC5)NC(=O)C6=CSC(C)=N6)C(=O)C7=C4N=CC(F)=C7)C[C@@H](C)N1
InChI
InChIKey=MKQDRXQEQLCSON-JFAUGGILSA-N
InChI=1S/C37H40FN7O3S/c1-22-18-43(19-23(2)40-22)20-25-7-9-26(10-8-25)27-5-4-6-31(15-27)44-34-32(16-28(38)17-39-34)36(47)45(37(44)48)30-13-11-29(12-14-30)42-35(46)33-21-49-24(3)41-33/h4-10,15-17,21-23,29-30,40H,11-14,18-20H2,1-3H3,(H,42,46)/t22-,23+,29-,30+
Indimilast is dioxodihydropyridopyrimidine derivative patented by global pharmaceutical company AstraZeneca as phosphodiesterase IV inhibitor. Indimilast modulates lung inflammation and causes bronchodilation by increasing intracellular cyclic adenosine 3', 5'-monophosphate in airway smooth muscle and inflammatory cells. Indimilast is potentially useful in chronic obstructive pulmonary disease but its activity was never evaluated in clinical trials.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C170065
Created by
admin on Mon Mar 31 18:35:15 GMT 2025 , Edited by admin on Mon Mar 31 18:35:15 GMT 2025
|
PRIMARY | |||
|
300000036902
Created by
admin on Mon Mar 31 18:35:15 GMT 2025 , Edited by admin on Mon Mar 31 18:35:15 GMT 2025
|
PRIMARY | |||
|
10054
Created by
admin on Mon Mar 31 18:35:15 GMT 2025 , Edited by admin on Mon Mar 31 18:35:15 GMT 2025
|
PRIMARY | |||
|
57690026
Created by
admin on Mon Mar 31 18:35:15 GMT 2025 , Edited by admin on Mon Mar 31 18:35:15 GMT 2025
|
PRIMARY | |||
|
1038825-85-2
Created by
admin on Mon Mar 31 18:35:15 GMT 2025 , Edited by admin on Mon Mar 31 18:35:15 GMT 2025
|
PRIMARY | |||
|
Y8P6XRV14P
Created by
admin on Mon Mar 31 18:35:15 GMT 2025 , Edited by admin on Mon Mar 31 18:35:15 GMT 2025
|
PRIMARY |
ACTIVE MOIETY